Category: MUMAK SpotLight

MUMAK SpotLight

MUMAK SpotLight of the week: TKMS, Palantir, and SpaceX in focus

TKMS impresses with strong figures and a raised outlook, while Palantir remains highly valued after the AI rally, and SpaceX
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Revolution Medicines with FDA breakthrough. PayPal and Palantir in focus

Revolution Medicines reaches a decisive milestone with the FDA approval of Daraxonrasib. PayPal loses a key short-term price driver as
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Eli Lilly and Palantir in focus

Eli Lilly strengthens its pipeline, Palantir remains volatile, and Johnson & Johnson gains momentum. The most important developments of the
Next Update
MUMAK SpotLight

MUMAK SpotLight of the Week: Apple and Amazon Quarterly Review

Apple and Amazon make a statement – strong quarterly results with differing market reactions
Next Update